Catalog No.
Product Name
Application
Product Information
Citations
-
IL-20/PRINS Inhibitor
Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. This compound demonstrates significant immune modulation, effectively reducing the proliferation rate of skin cells in psoriasis. It serves as a valuable tool for investigating inflammatory skin disorders and potential therapeutic strategies in related research applications. -
Gingerol
Diacetoxy-6-gingerdiol is a derivative of gingerol that exhibits anti-inflammatory and antioxidant properties. This compound has been shown to protect the extracellular matrix of nucleus pulposus cells and reduce intervertebral disc degeneration through the inhibition of the IL-1β-mediated NLRP3 pathway. Its research applications include investigating mechanisms of inflammation and extracellular matrix preservation in musculoskeletal disorders. -
PGE2 Antagonist
EP4 receptor antagonist 7 is a selective antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4, demonstrating an IC50 value of 1.1 nM. This compound effectively inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 of 0.9 nM and downregulates the expression of several important mRNAs, including IL-4 and Arg1, in RAW 264.7 macrophages. Additionally, EP4 receptor antagonist 7 shows potential in combination with anti-PD-1 antibodies to inhibit tumor growth and enhance CD8+ T cell infiltration in a CT26 murine colon cancer model, making it a valuable tool for cancer immunotherapy research. -
IL-1β Inhibitor
IL-1β-IN-2 is a potent inhibitor of interleukin-1 beta (IL-1β), a key mediator in inflammatory processes. This cannabigerol derivative exhibits significant anti-inflammatory and analgesic effects, making it a valuable tool for research into conditions driven by IL-1β signaling. IL-1β-IN-2 is suitable for studies focused on inflammatory diseases and pain management, aiding in the understanding and development of therapeutic strategies targeting IL-1β. -
Anti-Inflammatory Compound
12-Oxo phytodienoic acid (12-OPDA) is an anti-inflammatory compound derived from plant lipids. It effectively suppresses neuroinflammation by inhibiting the nuclear factor kappa-light-chain-enhancer of activated B cells (Nf-κB) and p38 mitogen-activated protein kinase (MAPK) pathways in lipopolysaccharide (LPS)-activated cells. This compound is valuable for research related to neurodegenerative diseases, enabling the exploration of therapeutic strategies targeting inflammatory responses. -
Anti-inflammatory Agents
Xanthomicrol is a monoamine oxidase (MAO) inhibitor derived from the resin of the Chinese bellflower (Scrophulariaceae family). It exhibits significant anti-inflammatory and anti-tumor activities, with IC50 values of 0.88 and 1.69 μg/mL in HL60 and K562 cells, respectively. Xanthomicrol has been shown to reduce both iNOS protein and mRNA levels, as well as COX-2 protein levels. Additionally, it diminishes the production of the pro-inflammatory cytokine IL-1β and upregulates the antioxidant enzyme HO-1, making it a valuable tool for research in inflammatory and cancer-related studies. -
Anti-inflammatory agent
Docosahexaenoyl serotonin (DHA-5-HT) functions as an anti-inflammatory agent through its inhibition of interleukin-17 (IL-17). This endogenous conjugate of n-3 fatty acid and serotonin exhibits significant anti-inflammatory properties. It is utilized in research to explore mechanisms related to inflammation and potential therapeutic applications for inflammatory diseases. -
CXCR2 Antagonist
Elubrixin is a potent and selective CXCR2 antagonist, functioning as a competitive and reversible inhibitor of the IL-8 receptor. It effectively impedes neutrophil CD11b upregulation with an IC50 of 260.7 nM and inhibits shape change with an IC50 of 310.5 nM. This compound is valuable in the study of inflammatory diseases, including inflammatory bowel disease and airway inflammation, facilitating insights into pathophysiological mechanisms and therapeutic interventions. -
Anti-inflammatory Agent
Anti-inflammatory Agent 42 (Compound 10j) is designed to inhibit pro-inflammatory cytokines, specifically targeting tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). This compound demonstrates significant efficacy in reducing cytokine expression in lipopolysaccharide (LPS)-stimulated macrophages, making it a valuable tool for research in inflammation and immune response studies. Its application extends to investigations aimed at understanding chronic inflammatory diseases and exploring therapeutic interventions. -
Anti-Inflammatory Compound
Cynandione A is an acetophenone compound with anti-inflammatory properties. It has been shown to protect hepatocytes and cortical neurons from toxicity, as well as improve neurological deficits in a rat model of cerebral ischemia. Additionally, Cynandione A exerts significant anti-inflammatory effects through the activation of macrophage α7 nAChR and the expression of IL-10, making it a valuable tool for research in neuroprotection and inflammation. -
IL-17 Modulator
IL-17 Modulator 1 disodium is a potent inhibitor targeting the IL-17 signaling pathway. This compound demonstrates significant biological activity in mitigating inflammatory responses, making it valuable for research applications related to autoimmune conditions such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. Its oral bioavailability further enhances its utility in preclinical studies aimed at understanding and developing therapies for IL-17 associated diseases. -
Anti-inflammatory Agent
Hydrocortisone hemisuccinate hydrate serves as an orally active glucocorticoid anti-inflammatory agent, primarily targeting and inhibiting pro-inflammatory cytokines such as IL-6 and IL-3 with IC50 values of 6.7 μM and 21.4 μM, respectively. This compound exhibits significant anti-inflammatory and immunomodulatory activities, making it valuable in research applications related to ulcerative colitis and recurrent oral ulcers. Its ability to modulate inflammation positions it as a key reagent for studies in inflammatory disease pathways. -
Anti-inflammatory Agent
4-Ethoxybenzaldehyde is an anti-inflammatory agent that serves as a derivative of benzaldehyde. This compound effectively inhibits the production of key inflammatory mediators, including prostaglandin E2 (PGE2), IL-6, and IL-8, induced by ultraviolet radiation (UVR). Its demonstrated efficacy and safety profile make it valuable for reducing facial redness in topical formulations, notably in oil-in-water emulsions at a concentration of 1%. 4-Ethoxybenzaldehyde is suitable for research on chronic inflammatory skin diseases. -
IL-1β Inhibitor
IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications. -
IL-17 Inhibitor
IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways. -
Anti-IL-17C Antibody
MOR-106 is a humanized anti-IL-17C IgG1 monoclonal antibody that targets interleukin-17C, a cytokine involved in inflammatory responses. By binding specifically to IL-17C, MOR-106 inhibits the NF-κB signaling pathway, demonstrating an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. This reagent effectively reduces skin inflammation and associated inflammatory factors in preclinical models of psoriasis and atopic dermatitis, making it a valuable tool for research into inflammatory skin disorders. -
Anti-inflammatory Agent
Arvelexin is an anti-inflammatory agent that primarily acts by inhibiting NF-κB activation. Isolated from Brassica rapa L. (Brassicaceae), Arvelexin also downregulates the expression of IL-8, making it a valuable compound for research into colonic inflammation. This compound is of interest for studies focused on inflammatory pathways and potential therapeutic applications in inflammatory bowel disease and related disorders. -
IL-17 Modulator
IL-17 Modulator 4 Sulfate targets the IL-17 signaling pathway, functioning as a proagent of IL-17 Modulator 1. This compound exhibits potent modulatory effects on IL-17A, making it a valuable tool for investigating IL-17A mediated diseases. Its applications extend across various fields, including inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes, facilitating a deeper understanding of these conditions. -
CD25 ADC
Camidanlumab tesirine is an antibody-drug conjugate (ADC) that targets CD25, utilizing the HuMax-TAC human IgG1 monoclonal antibody. This compound is conjugated via a cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer, achieving a drug-antibody ratio of 2.3. Camidanlumab tesirine demonstrates exceptional affinity for human CD25 at the picomolar level and exhibits potent cytotoxic effects against various CD25-expressing human lymphoma cell lines, positioning it as a promising candidate for targeted cancer therapies. -
Anti-IL-15RA Antibody
Larnefpendekin alfa is an anti-IL-15RA antibody designed to target and inhibit the interleukin-15 receptor alpha (IL-15RA). This fusion protein plays a pivotal role in modulating immune responses by interfering with IL-15 signaling pathways. Its primary applications include investigations into immune system regulation, potential therapeutic avenues in autoimmune diseases, and cancer immunotherapy. This reagent is valuable for research focused on cytokine interactions and immune cell activation. -
CXCR2 Antagonist
Elubrixin hydrochloride is a potent, selective CXCR2 antagonist that operates as a competitive, reversible inhibitor of the IL-8 receptor. It effectively inhibits neutrophil CD11b upregulation and shape change, with an IC50 of 260.7 nM and 310.5 nM, respectively. This compound is valuable for research applications related to inflammatory diseases, including inflammatory bowel disease and airway inflammation. -
IL-2 Antibody Inhibitor
Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses. -
IL-17 Inhibitor
IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways. -
IL-1 Inhibitor
Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications. -
CSF1R/Mer/Axl Inhibitor
Adrixetinib is a potent triple inhibitor targeting CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM respectively. This compound serves as an effective immune modulator by remodeling the tumor microenvironment, enhancing the presence of M1 macrophages and CD8⁺ T cells while reducing M2 macrophages and myeloid-derived suppressor cells (MDSCs). Additionally, Adrixetinib increases the expression of MHC class I and E-cadherin in tumor cells, demonstrating significant antitumor efficacy in syngeneic mouse models. It is relevant for research involving breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma. -
CD44-Hyaluronan Inhibitor
IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration. -
CD31 Agonist
P8RI is a biomimetic peptide that acts as a CD31 agonist. By binding to the juxtamembrane amino acid sequence of the ectodomain of CD31, P8RI restores the CD31 inhibitory pathway, exhibiting significant immunosuppressive effects. This compound is useful for research applications focused on immune modulation and the exploration of CD31-related pathways in cellular processes. -
CXCR4 Antagonist
Burixafor hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4, effectively inhibiting the binding of CXCL12 to the CXCR4 receptor. This compound antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, thereby obstructing the downstream Gαᵢ-mediated inhibition of cAMP signaling. Burixafor hydrobromide is utilized in research for mobilizing CD34+ hematopoietic stem/progenitor cells from the bone marrow to peripheral blood, making it valuable in studies related to autologous hematopoietic stem cell transplantation. -
Oxidative Stress Modulator/Anti-inflammatory Agent
Guluronic acid is an oxidative stress modulator and anti-inflammatory agent. It functions by down-regulating pro-inflammatory genes such as TLR4, NF-κB, and iNOS, while inhibiting COX-2, MMPs, and VEGF activity. This compound promotes the up-regulation of immunoregulatory genes including SHIP1 and SOCS1, thereby mitigating cancer-related inflammation, tumor angiogenesis, cell adhesion, and metastasis, while decreasing immunosuppressive cell accumulation. Guluronic acid has demonstrated potential in extending survival times in tumor-bearing hosts within a non-cytotoxic concentration range and has applications in research related to multiple sclerosis, ankylosing spondylitis, breast cancer, and other inflammatory diseases. -
COX Inhibitor
(±)-Aiphanol is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 (IC50 = 1.9 μM) and COX-2 (IC50 = 9.9 μM). This compound displays significant anti-inflammatory properties and further inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 0.92 μM. By impeding both COX-2 and VEGFR2 pathways, (±)-Aiphanol effectively blocks angiogenesis and induces apoptosis, making it a valuable tool in the study of inflammatory diseases and cancer research. The compound demonstrates oral bioactivity, enhancing its potential for in vivo applications. -
Anti-VEGFR2/KDR/CD309 Antibody
Girancitug is a humanized IgG1κ monoclonal antibody that specifically targets the vascular endothelial growth factor receptor 2 (VEGFR2/KDR/CD309). It effectively inhibits angiogenesis, making it a valuable tool in cancer research. Girancitug is applicable in anti-angiogenic therapy studies, particularly for cancers such as colorectal and ovarian cancers. -
Keap1-Nrf2 Inhibitor
Keap1-Nrf2-IN-11 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting a KD2 value of 0.21 nM. This compound effectively reduces the production of reactive oxygen species (ROS) and nitric oxide (NO), as well as downregulating the expression of tumor necrosis factor-alpha (TNF-α). By promoting Nrf2 nuclear translocation, Keap1-Nrf2-IN-11 demonstrates significant anti-inflammatory properties, making it a valuable tool for research in inflammation-related pathways. -
Anti-inflammatory Agent
Anti-inflammatory agent 64 targets the inhibition of pro-inflammatory cytokines, specifically IL-6 and TNF-α. This compound exhibits both antioxidant and anti-inflammatory activity in vitro and in vivo, making it a valuable tool for studying inflammatory processes. Additionally, it has been shown to significantly reduce paw edema, highlighting its potential utility in therapeutic research for inflammatory diseases. -
Complement factor B synthesis reducer
Agazisiran is a small interfering RNA (siRNA) that targets and reduces the synthesis of complement factor B, a key component in the alternative complement pathway. By modulating complement activation, Agazisiran has potential applications in research focused on autoimmune diseases, inflammatory conditions, and other disorders where complement dysregulation plays a critical role. -
Complement Inhibitor
3-Phenoxybenzaldehyde is a compound identified as a complement inhibitor, exhibiting weak inhibition of the classical pathway of the complement system. This compound demonstrates hemolytic activity, making it relevant for studies related to immune response modulation and complement pathway research. Its applications extend to investigations in autoimmune diseases and therapies targeting complement-mediated cytotoxicity. -
C5 Complement Inhibitor
Avacincaptad pegol is a pegylated RNA aptamer that selectively inhibits complement component C5. By preventing the cleavage of C5 into pro-inflammatory fragments C5a and C5b, this compound mitigates inflammatory cell recruitment and reduces retinal cell damage. Avacincaptad pegol has demonstrated potential in slowing the progression of geographic atrophy (GA) lesions and decreasing the risk of vision loss, making it a valuable tool for research involving age-related macular degeneration (AMD). -
CD11b Agonist
(Z)-Leukadherin-1 is a potent allosteric agonist of CD11b that exhibits oral bioavailability. This compound effectively repolarizes tumor-associated macrophages, diminishes the presence of immunosuppressive myeloid cells within tumors, and enhances the activation of dendritic cells. It serves as a valuable reagent for research in immuno-oncology, exploring mechanisms of immune modulation and macrophage plasticity. -
Complement System Inhibitor
Factor B-IN-1 is an inhibitor of Factor B, targeting the complement system to modulate its activity. This compound demonstrates significant inhibition of the alternative pathway of complement activation, making it a valuable tool for studying complement-mediated diseases and immune responses. Factor B-IN-1 is suitable for use in research applications focused on therapeutic interventions and the development of complement-targeted therapies. -
Anti-complement Activator
Entadamide-A-β-D-glucopyranoside serves as an anti-complement activator, derived from the seeds of Entada phaseoloides. This compound exhibits significant biological activity by inhibiting complement activation, making it a valuable tool for research in immunology and inflammation. Its applications extend to studies focused on understanding the roles of the complement system in various diseases. -
Complement Factor D Inhibitor
Complement Factor D-IN-2 is an inhibitor targeting complement factor D, effectively interrupting the complement cascade at a critical juncture within the alternative complement pathway. By inhibiting factor D, this compound presents valuable opportunities for investigating the role of complement activation in autoimmune diseases. Researchers can utilize Complement Factor D-IN-2 to explore therapeutic strategies aimed at modulating immune responses and mitigating the progression of complement-mediated pathologies. -
Pro-Inflammatory Peptide
C5a Anaphylatoxin (human) is a pro-inflammatory peptide that functions as a potent leukocyte chemoattractant. It plays a significant role in mediating inflammatory responses and can be employed in research related to various immune system disorders, including allergic asthma. This reagent is ideal for studies investigating the mechanisms of inflammation and the effects of immune modulation. -
Human Complement C5
Human complement C5 is a crucial component of the complement system, acting as a precursor to both the C5a anaphylatoxin and C5b, which play pivotal roles in immune responses. This protein is integral to the activation of the complement cascade, facilitating phagocytosis and the destruction of pathogens while enhancing adaptive immunity. Its study is essential for understanding immune system functions and developing therapeutic strategies against various diseases. -
Complement Factor D Inhibitor
Refinicopan is a selective inhibitor of complement factor D, demonstrating an IC50 of 10 nM. This compound effectively inhibits rabbit erythrocyte hemolysis with an IC50 of 41 nM, indicating its capacity to modulate complement-mediated processes. Refinicopan's favorable pharmacokinetic and pharmacodynamic properties make it a valuable tool for investigating complement-related disorders and potential therapeutic interventions. -
Complement Protein C5 Inhibitor
Vensobafusp alfa is a fusion protein that targets complement protein C5, functioning as a potent inhibitor. It combines an IgG4 monoclonal antibody directed against C5 with the complement factor H 1-5 domain, demonstrating significant anti-inflammatory and immunomodulatory properties. This reagent is applicable in the study of complement-mediated pathologies and therapeutic strategies targeting inflammatory conditions. -
Anticomplement Agent
3-O-(2'E,4'Z-Decadienoyl)ingenol is a natural diterpene that functions as an anticomplement agent, demonstrating significant inhibitory activity with an IC50 of 89.5 μM. This compound is primarily utilized in research applications focused on complement system modulation and potential therapeutic interventions related to autoimmune conditions and inflammation. Its unique mechanism of action offers valuable insights into complement-related pathways in various biological contexts. -
Complement component 3 (C3) synthesis reducer
Cevolisiran is a small interfering RNA (siRNA) that specifically targets and reduces the synthesis of complement component 3 (C3). This reduction in C3 levels may modulate the complement pathway, which is pivotal in immune responses and inflammation. Cevolisiran is primarily used in research applications aimed at understanding the role of the complement system in various diseases and therapeutic strategies. -
Complement System Inhibitor
Bisphenol A bissulfate disodium is a complement system inhibitor with a significant role in modulating immune responses. This compound exhibits complement-inhibiting activity, demonstrating an IC50 value of 247 μM. It is utilized in research applications aimed at understanding the complement pathway and its implications in various diseases, making it a valuable tool in immunological studies. -
Complement inhibitor
Bisphenol S disulfate disodium is a complement inhibitor that exhibits a half-maximal inhibitory concentration (IC50) of 660 μM. This compound is utilized in research applications aiming to explore complement-mediated pathways and their roles in various biological processes and diseases. Its ability to modulate complement activity makes it a valuable tool for studies involving immune response and inflammation. -
TLR9 Agonist
Agatolimod sodium, a TLR9 agonist, is classified as a class B CpG oligodeoxynucleotide (ODN 2006). It enhances immune responses and is widely utilized as a vaccine adjuvant. In addition, Agatolimod sodium serves as a valuable tool in cancer research, aiding studies aimed at understanding tumor immunology. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’. -
TLR7/8 Inhibitor
Enpatoran is a potent and orally active dual inhibitor of Toll-like receptors 7 and 8, exhibiting IC50 values of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. This compound is selective, showing no activity against TLR3, TLR4, or TLR9. Enpatoran effectively blocks both synthetic and natural RNA ligands, demonstrating excellent pharmacokinetic properties in vivo. It is a valuable tool for research focused on modulating innate and adaptive immune responses related to autoimmunity.
